33results about How to "Maintain therapeutic effect" patented technology

By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.

The present invention provides prodrug and multiprodrug complexes comprising drugs specifically bound to synthetic receptors in such a manner that active drug becomes available only in the presence of a targeted pathophysiologic receptor. Methods for preparation end use of these prodrug complexes in drug delivery systems are also provided.

The invention provides a female urine collector which comprises a urine collecting hopper. The bottom of the urine collecting hopper is connected with a urine tube. The bottom end of the urine tube is provided with a connector. The connector comprises a column body. An inner cavity is formed in the column body. The upper end and the lower end of the column body are provided with ports communicated with the inner cavity. The upper port of the column body is provided with a nut. The bottom of the nut is provided with an insertion core. A hole communicated with the inner cavity of the column body is formed in the nut. A check valve is arranged in the urine tube. The portion, at the lower end of the check valve, of the urine tube is connected with an air bag through an air tube. By means of the female urine collector, the problems that urinary tract system infection, eczema and the like are caused to females when a urine tube is inserted or a baby diaper is worn can be reduced. The female urine collector is particularly designed for female patients and is reasonable in structure and convenient to use, the physiological problems of the female patients suffering from aconuresis can be effectively solved, complications caused by nursing and treatment are avoided, comfort level of treatment is improved for patients, and patients are helped to recover as soon as possible.

The invention relates to an oral pharmaceutical composition comprising the combination of an ibuprofen salt or S(+)-ibuprofen with L-arginine and/or the pharmaceutically acceptable salts thereof, and additionally pharmaceutically acceptable vehicles and/or excipients. The invention also relates to the method of producing the composition and to the use of said composition having synergic therapeutic activity, for treating moderate to severe inflammatory pain, fever and inflammation.

The present invention discloses a hair-blackening cake and its production process. Its raw material composition includes (by wt%) 60-75% of glutinous rice, 15-25% of white sugar, 3-10% of prepared flowery knotweed root and 3-10% of black sesame, and its production process includes the following steps: preparing raw materials, stirring and mixing raw material, forming, cutting, baking and packaging.

Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies.

The present invention provides a combined drug for an injectable depot formulation having a superior effect of preventing and/or treating polycystic kidney disease. More specifically, the present invention relates to a drug for preventing and/or treating polycystic kidney disease, which is an injectable depot formulation comprising a particle containing tolvaptan or a prodrug thereof and a somatostatin analogue. The present invention also relates to a method for preventing and/or treating polycystic kidney disease using the drug.

The present invention relates to a backing having a three-layer structure prepared by sticking together an inner fiber layer for holding a pasty preparation, a film layer having through-holes, and an air-permeable outer fiber layer which prevents leaking out of the pasty preparation or a liquid component exuded from the pasty preparation, and also relates to an aqueous patch using the backing which can be applied for a long time.

Pharmaceutical particles having an inner portion comprising an agonist of peroxisome proliferator-activated receptor α (PPARα) and a biodegradable polymer; and an outer coating comprising an emulsifier which surrounds the inner portion, wherein the agonist may be a fibrate, and the particle contains at least about 5 wt % to about 25 wt % of the agonist, and wherein the particle has a sustained delayed release of the agonist in a range of at least about 1 to 12 months when in an aqueous solution or physiological environment. The pharmaceutical particles may be used, for example, to treat diseases and conditions such as ocular disorders which benefit from PPARα agonist.

The invention discloses a ceramide E emulsifier as well as a preparation method and application thereof in cosmetics. The ceramide E emulsifier comprises the following components: 0.1-5% of ceramide E, 0-2% of lecithin, 8-25% of a humectant, 5-10% of an emulsifier, 0-2% of an auxiliary agent and the balance of water. The preparation method comprises the following steps: stirring and wetting the lecithin and the ceramide E by using the humectant, heating and dissolving, adding the remaining materials, shearing and dispersing uniformly in a heating state, and treating by using a microjet homogenizer to obtain the semitransparent or transparent ceramide E emulsifier. The ceramide E emulsifier disclosed by the invention has good stability, water dispersibility and biocompatibility, and can be widely applied to the cosmetic industry.

The invention relates to a multistage purification intelligent insect-resistance and corrosion-resistance electronic source tracing Chinese herbal medicine storage system. The system comprises an intelligent control chamber provided with an industrial personal computer PLC, a multistage laminar purifying chamber, a goods storage core area and a storage buffer area. The industrial personal computer PLC is connected with an intelligent control sensor, a double-system and high-efficiency insect inhibition generator in the multistage laminar purifying chamber, an electronic source tracing code scanner, a data integration display screen, a temperature/humidity sensor, a self-control closed ventilation window and the like by electric input cables. A high-efficiency air filter is distributed at the external of a wall of the multistage laminar purifying chamber. The electronic source tracing code scanner is connected with a Chinese herbal medicine source tracing management system port and an internet, and updates data in real time by a console. The system effectively solves the problems of easiness in insect and mould generation and color change in storage of Chinese herbal medicines, overcomes multiple defects in traditional methods, improves the production efficiency, reduces the labor intensity, prevents loss of effective components of the Chinese herbal medicines and loss of a lot of materials, and can be suitable for storage of the Chinese herbal medicines with various specifications.

The invention belongs to the technical field of medicines, and particularly relates to a bear gall sugar-free lozenge as well as a preparation method and application thereof. The bear gall sugar-free buccal tablet comprises the following components in parts by weight: 50-100 parts of a bear gall raw material, 250-600 parts of beta-cyclodextrin, 280-680 parts of dextrin, 3-8 parts of steviosin, 4-8 parts of menthol, 4-8 parts of peppermint oil, 2-4 parts of magnesium stearate, 4-8 parts of talcum powder and 3-6 parts of essence. The bear gall raw material is bear bile or bear gall powder. The bear gall is used as a main component, other appropriate auxiliary materials are preferentially matched, the prepared bear gall sugar-free lozenge is good in taste, the original components and style of the bear gall are kept, the natural physiological activity and the specific treatment effect of the bear gall are also kept, the problems of bitter taste, fishy taste and damp taste of the bear gall and the bear gall in a preparation are fundamentally solved, the quality is stable, and the traditional Chinese medicine composition is suitable for children, old people and diabetics to take.

The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising

wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol.

Provided herein is a novel method for creating fixed, non-antagonistic molar ratios of drugs in and around the bone environment for desired periods of time. This method enables treating bone and bone-related disease by administering a pharmaceutical composition comprising a bone-targeted therapeutic agent able to release a drug payload from the bone surface, in addition to a second therapeutic agent. Such methods are useful in the treatment of bone and bone-related diseases, such as cancer-induced bone disease, osteomyelitis and bone infection, bone pain and inflammatory bone disease, metabolic disease, as well as others.

The present invention relates to a treatment apparatus including a housing, an insertion unit provided on one side of the housing and formed to be inserted into a tissue through a tissue surface, and a cooling unit cooling the one side of the insertion unit within the housing to prevent thermal damage to the tissue touched when the insertion unit heated during a treatment time is drawn out from or inserted into the tissue, and a method of controlling the same and a treatment method. According to the present invention have effects in that they can prevent a problem in that unnecessary damage to a tissue occurs while maintaining a treatment effect of the skin because the heated end of the insertion unit is cooled and moved.